Predictive
Oncology (NASDAQ: POAI) is assisting clinicians and researchers in
improving outcomes for cancer patients via its AI-driven, tumor-profiling
platform. A recent article discussing the company reads, “POAI’s technology
combines its database of evidence documenting actual drug responses of cancer
patients’ tumors with artificial intelligence (AI) to create an invaluable
predictive tool for clinicians and researchers. Predictive Oncology’s data
offers a valuable, customizable assessment method that can be used by
oncologists to determine the best drug for fighting a specific patient’s
cancer. This disruptive technology is the first of its kind and is also meeting
a critical need in the pharmaceutical, diagnostic and biotech industries to
speed up the search for new precision therapies by providing tools to better
predict how new drugs work on different cancers (http://ibn.fm/0YnNI). . . . POAI’s wholly owned
subsidiaries — Helomics and TumorGenesis — are working together to bring these
important precision-medicine tools to physicians.”
To view the full article, visit http://ibn.fm/rh8Cw
About Predictive Oncology Inc.
Predictive Oncology (formerly Precision Therapeutics Inc.)
operates through its three business units: Helomics, TumorGenesis and Skyline
Medical. Helomics applies artificial intelligence to rich data gathered from
patient tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary
precision-oncology platform, Helomics offers boutique CRO services that
leverage its TruTumor, patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in
TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient-specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA-cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment